SION · Sionna Therapeutics, Inc. · Share Buybacks
$3.60
-0.20 (-5.26%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$162.76M
Shares
45.21M
Volume · Oct 23
918.2K
Avg daily vol (3M)
2.24M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-03 | — | $250,000,000 | — | — | 10-Q , filed 2026-08-06 |
Key facts
CIK
2036042
CUSIP
829401108
13F (30d)
14 filings
14 filers
Visit website
Investor relations